Cardiovascular diseases (CVDs) are responsible for a large proportion of premature deaths in low- and middle-income countries. Early CVD detection and intervention is critical in these populations, yet many existing CVD risk scores require a physical examination or lab measurements, which can be challenging in such health systems due to limited accessibility. Here we investigated the potential to use photoplethysmography (PPG), a sensing technology available on most smartphones that can potentially enable large-scale screening at low cost, for CVD risk prediction. We developed a deep learning PPG-based CVD risk score (DLS) to predict the probability of having major adverse cardiovascular events (MACE: non-fatal myocardial infarction, stroke, and cardiovascular death) within ten years, given only age, sex, smoking status and PPG as predictors. We compared the DLS with the office-based refit-WHO score, which adopts the shared predictors from WHO and Globorisk scores (age, sex, smoking status, height, weight and systolic blood pressure) but refitted on the UK Biobank (UKB) cohort. In UKB cohort, DLS's C-statistic (71.1%, 95% CI 69.9-72.4) was non-inferior to office-based refit-WHO score (70.9%, 95% CI 69.7-72.2; non-inferiority margin of 2.5%, p<0.01). The calibration of the DLS was satisfactory, with a 1.8% mean absolute calibration error. Adding DLS features to the office-based score increased the C-statistic by 1.0% (95% CI 0.6-1.4). DLS predicts ten-year MACE risk comparable with the office-based refit-WHO score. It provides a proof-of-concept and suggests the potential of a PPG-based approach strategies for community-based primary prevention in resource-limited regions.

Cardiovascular disease is the leading cause of death globally, resulting in 17 million deaths each year. Despite the availability of various treatment options, existing techniques based upon conventional medical knowledge often fail to identify patients who might have benefited from more aggressive therapy. In this paper, we describe and evaluate a novel unsupervised machine learning approach for cardiac risk stratification. The key idea of our approach is to avoid specialized medical knowledge, and assess patient risk using symbolic mismatch, a new metric to assess similarity in long-term time-series activity. We hypothesize that high risk patients can be identified using symbolic mismatch, as individuals in a population with unusual long-term physiological activity.

Heart Test Laboratories, d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, announced that an independent study utilizing its MyoVista proprietary technology was featured in Advocate Aurora Health's Journal of Patient-Centered Research and Reviews, an open access, peer-reviewed medical journal devoted to advancing patient centered care practices, health outcomes, and patient experiences. The publication concluded that the MyoVista technology ECG-derived machine learning model "provides a cost-effective strategy for predicting patient subgroups in whom an integrated milieu of systolic and diastolic dysfunction is associated with a high-risk of major adverse cardiovascular events (MACE)." "This independent study demonstrates the opportunity that AI-ECG algorithms could bring to improving health outcomes. I believe the solution to unnecessary cardiac deaths will come from low-cost, front-line screening using AI-ECGs. Imagine the day where you can go to your primary care physician and a simple 20-second ECG test shows not only whether you have early-stage heart disease, but also whether you are at high-risk of a major adverse cardiovascular event in the next three years," stated Andrew Simpson, CEO of HeartSciences.

Cardiovascular disease is the leading cause of death globally, resulting in 17 million deaths each year. Despite the availability of various treatment options, existing techniques based upon conventional medical knowledge often fail to identify patients who might have benefited from more aggressive therapy. In this paper, we describe and evaluate a novel unsupervised machine learning approach for cardiac risk stratification. The key idea of our approach is to avoid specialized medical knowledge, and assess patient risk using symbolic mismatch, a new metric to assess similarity in long-term time-series activity. We hypothesize that high risk patients can be identified using symbolic mismatch, as individuals in a population with unusual long-term physiological activity.